Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO044 in Duchenne Muscular Dystrophy
NCT01037309Phase 2Completed
- Sponsor
- BioMarin Pharmaceutical
- Start
- Dec 2009
- Primary completion
- May 2013
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 4
01
Overview
Phase 2, open-label trial of PRO044 in Duchenne muscular dystrophy (DMD) (9 arms), sponsored by BioMarin Pharmaceutical. Primary endpoints: Increase in Dystrophin Expression in the Muscle Biopsies and Safety and Tolerability of PRO044. Started Dec 2009; status: completed.
02
Drugs
PRO044
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT01037309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01037309.